News

Sutro Marks Two Drug Development Milestones

Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone.. Read More →

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

Will Rapidly Advance Promising Drug Candidates to the Clinic   SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its.. Read More →

Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors

Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors.. Read More →

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts

STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma   SOUTH SAN FRANCISCO, July 17, 2017.. Read More →

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize? – InVivo

https://invivo.pharmamedtechbi.com/IV005100/Cancers-NextGen-Smart-Bomb-Who-Will-Be-First-To-Weaponize    .. Read More →

Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century

Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves.. Read More →

Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors

SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific.. Read More →

Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple myeloma, diffuse.. Read More →

SutroVax Announces Closing of $64M via Series B Financing

Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious.. Read More →

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma

SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001,.. Read More →

BioTech Nation Radio with CEO Bill Newell

NPR and BioTech Nation interview Sutro’s CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the.. Read More →

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma

SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it.. Read More →

Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene

SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene).. Read More →

Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer

SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical.. Read More →

Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development

SOUTH SAN FRANCISCO, Mar. 9, 2016 – Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark.. Read More →

Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ — Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon.. Read More →

Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management

SAN FRANCISCO, Aug. 4, 2015 – Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice president of alliance and project management... Read More →

SutroVax raises $22 million in Series A

Press release published by SutroVax, Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology Read more.. Read More →

Production of bispecific antibodies in “knobs-into- holes” using a cell-free expression system

Yiren Xu, John Lee, Cuong Tran, Tyler H Heibeck, Willie D Wang, Junhao Yang, Ryan L Stafford, Alexander R Steiner, Aaron K Sato, Trevor J Hallam,.. Read More →

Methods to Make Homogenous Antibody Drug Conjugates

Toni Kline, Alexander R. Steiner, Kalyani Penta, Aaron K. Sato, Trevor J. Hallam, Gang Yin,  Methods to Make Homogenous Antibody Drug Conjugates Pharmaceutical Research December 2014,.. Read More →

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit   SOUTH SAN FRANCISCO, Oct.. Read More →

FierceBiotech names Sutro Biopharma as one of its “Fierce 15” Biotech Companies of 2014

  San Francisco, CA – September 22, 2014 – Sutro Biopharma today announced that it has been named by FierceBiotech as one of 2014’s Fierce.. Read More →

A General Sequence Processing and Analysis Program for Protein Engineering

Ryan L. Stafford,* Erik S. Zimmerman, Trevor J. Hallam, and Aaron K. Sato, A General Sequence Processing and Analysis Program for Protein Engineering, dx.doi.org/10.1021/ci500362s | J... Read More →

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand.. Read More →

Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member

Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform Xpress CF™  SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing.. Read More →

Sutro Biopharma’s Xpress CF Technology Nominated for Best Scientific Innovation by World ADC

On July 1, 2014, World ADC announced the nominees for the World ADC Awards, 2014. Sutro Biopharma’s cell free expression system, Xpress CF™, has made.. Read More →

EnWave Signs Commercial License with Sutro Biopharma for powderREV® Technology

Press release published by EnWave Corporation regarding the recent agreement with Sutro Biopharma, Inc. Read more.. Read More →

Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference

SAN FRANCISCO, Mar. 24, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies,.. Read More →

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma

SAN FRANCISCO, Jan. 07, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies,.. Read More →

Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products

SAN FRANCISCO, Dec. 11, 2013 – Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will.. Read More →

Sutro Biopharma Presents Dual-Warhead Antibody Drug Conjugate at the World ADC Summit

SAN FRANCISCO, Oct. 15, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, presented today.. Read More →

Producing Homogeneous ADCs with Combination Warheads

Hallam, Trevor, Producing Homogeneous ADCs with Combination Warheads Presented at the 4th World ADC Summit, San Francisco (PDF) Read More.. Read More →

Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter

Scientific American Guest Blog Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter By: Trevor J. Hallam Read More.. Read More →

Cell-free translation of peptides and proteins: from high throughput screening to clinical production

Christopher J Murray, and Ramesh Baliga, Cell-free translation of peptides and proteins: from high throughput screening to clinical production,  Current Opinion in Chemical Biology 2013,.. Read More →

Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer

SAN FRANCISCO, Jan. 31, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, today announced.. Read More →

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

SAN FRANCISCO, Jan. 3, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, today announced.. Read More →

Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies

SAN FRANCISCO, Dec. 18, 2012 – Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific.. Read More →

Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research

SAN FRANCISCO, October 24, 2012 – Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted.. Read More →

Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs

Hallam, Trevor, Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs. Presented at the 3rd World ADC Summit, San Francisco.. Read More →

Sutro Closes $16.5 Million Second Tranche of Series C Financing

SAN FRANCISCO, May 8, 2012 – Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was.. Read More →

Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system

Gang Yin, Eudean D. Garces, Junhao Yang, Juan Zhang, Cuong Tran, Alexander R. Steiner, Christine Roos, Sunil Bajad, Susan Hudak, Kalyani Penta, James Zawada, Sonia.. Read More →

Sutro Announces Newly Formed Scientific Advisory Board Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline

SAN FRANCISCO, Jan. 7, 2012 – Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has.. Read More →

Sutro Biopharma’s Trevor Hallam offers a glimpse into the future of drug design

12/5/2011 – BioPharm International Podcast (3of3): Sutro Biopharma’s Trevor Hallam offers a glimpse into the future of drug design By: Trevor J. Hallam Listen Now.. Read More →

Sutro Biopharma’s Trevor Hallam describes a future cGMP manufacturing facility

BioPharm International Podcast (2of3): Sutro Biopharma’s Trevor Hallam describes a future cGMP manufacturing facility By: Trevor J. Hallam Listen Now.. Read More →

Sutro Biopharma and Cell-Free Protein Expression Systems

BioPharm International Podcast (1of3): Sutro Biopharma and Cell-Free Protein Expression Systems By: Trevor J. Hallam Listen Now.. Read More →

Preparation and Testing of E. coli S30 In Vitro Transcription Translation Extracts

James F. Zawada, Preparation and Testing of E. coli S30 In Vitro Transcription Translation Extracts Ribosome Display and Related Technologies Methods in Molecular Biology Volume.. Read More →

Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin

SAN FRANCISCO, Oct. 17, 2011 – Sutro’s Chief Scientific Officer, Trevor Hallam, Ph.D., to Highlight Company’s Technology Platform for the Highly Specific Design and Manufacturing of.. Read More →

Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production: A New Approach for Shortening Protein Production Development Timelines

James F. Zawada, Gang Yin, Alexander R. Steiner, Junhao Yang, Alpana Naresh, Sushmita M. Roy, Daniel S. Gold, Henry G. Heinsohn, Christopher J. Murray, Microscale.. Read More →

Industrializing Design, Development, and Manufacturing of Therapeutic Proteins

PHARMACEUTICAL TECHNOLOGY Volume 35, pp. s8-s11 Industrializing Design, Development, and Manufacturing of Therapeutic Proteins By: Trevor J. Hallam, Christopher J. Murray. Read more.. Read More →

“Unnatural Selection”

BioCentury, The Bernstein Report on BioBusiness January 10, 2011 issue article, “Unnatural Selection” in the Tools & Techniques section by BioCentury Senior Editor, Ms. Susan.. Read More →

Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.

San Francisco, CA Jan. 7, 2011 – Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the.. Read More →

Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics

San Francisco, CA Dec. 8, 2010 – Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that.. Read More →

A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies

Garces, Eudean et. al., A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies. Presented at the IBC.. Read More →

Sutro Biopharma Secures $36.5 Million in Series C Financing

South San Francisco, CA Nov. 17, 2010 – Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will.. Read More →

Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS

Heibeck, Tyler H., et. al., Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS. 58th American Society for Mass Spectrometry Conference on.. Read More →

Towards scalable cell-free synthesis of non-native amino acid containing proteins

Rozzelle, James E., et.al., Towards scalable cell-free synthesis of non-native amino acid containing proteins. Presented at American Chemical Society Spring Meeting, San Francisco, CA. Read.. Read More →

Sutro Biopharma and Promising Protein Synthesis Technology

National Science Foundation (NSF) newsletter featuring Sutro Biopharma and Promising Protein Synthesis Technology. Read more.. Read More →

Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team

South San Francisco, CA (August 20, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced.. Read More →

Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices — Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production —

South San Francisco, CA (June 9, 2009) Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, announced today.. Read More →

Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology * Milestone Triggers $15 Million Series B Financing

South San Francisco, CA (March 30, 2009) Sutro Biopharma, Inc., a pioneer in open cell-free synthesis for the discovery and production of proteins, announced today the.. Read More →

William J. Newell Named Chief Executive Officer of Sutro Biopharma * Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer * Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco

South San Francisco, CA (January 12, 2009) Sutro Biopharma, Inc., formerly known as Fundamental Applied Biology, today announced the appointment of William J. Newell as Chief.. Read More →